Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more

Conditions: Diabetic Foot
Interventions: SkinTE, Control; Biological · Other
Lead sponsor: PolarityTE; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 23
States / cities: Mesa, Arizona • Castro Valley, California • Fresno, California + 19 more

Conditions: PARKINSON DISEASE (Disorder)
Interventions: Prescriptive Infusion Algorithm, AB-1005; Procedure · Drug
Lead sponsor: AskBio Inc; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Neoplasms
Interventions: [177Lu]-NeoB, [68Ga]-NeoB, LCZ696; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Baltimore, Maryland + 3 more

Conditions: Uveitis, Anterior
Interventions: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System, EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 10 more

Conditions: Trichomonas Infection
Interventions: Secnidazole, Placebo; Drug
Lead sponsor: Lupin Research Inc; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • North Miami, Florida • Chicago, Illinois + 7 more

Conditions: Chlamydia Trachomatis, Gonorrhea
Interventions: Atlas Genetics io® system; Device
Lead sponsor: Binx Health Limited; Industry
Eligibility: 14 Years and older
Enrollment: 7,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 7 more

Conditions: Advanced Cholangiocarcinoma
Interventions: Pembrolizumab, Sylatron; Drug
Lead sponsor: Aiwu Ruth He, MD; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Parkinson Disease
Interventions: HBI-002, Vehicle (placebo); Drug
Lead sponsor: Hillhurst Biopharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more

Conditions: Hypotension, Orthostatic
Interventions: Midodrine hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 19 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Fort Wayne, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 8 more

Conditions: Chronic Angina
Interventions: Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 23 more

Conditions: Acne Vulgaris
Interventions: Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT; Drug · Procedure
Lead sponsor: Photocure; Industry
Eligibility: 9 Years to 35 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more

Conditions: Allergic Rhinitis Due to Grass Pollens
Interventions: 300 IR, Placebo; Drug
Lead sponsor: Stallergenes Greer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more

Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Conditions: Alzheimer's Disease in Down Syndrome
Interventions: Not listed
Lead sponsor: LuMind IDSC Foundation; Other
Eligibility: 25 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 11 more

Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Interventions: Serostim; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Beach, California + 18 more

Conditions: Asthma
Interventions: FF/GSK573719, FF, FF/VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more

Conditions: Leiomyoma
Interventions: BAY1002670, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more

Conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Interventions: MRG002; Drug
Lead sponsor: Shanghai Miracogen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Orange, California • Houston, Texas

Conditions: Dry Eye Disease
Interventions: K-161, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 45 more

Conditions: Hepatitis C, Chronic
Interventions: Interleukin 28B testing; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Migraine Disorders
Interventions: DaxibotulinumtoxinA; Drug
Lead sponsor: Ki Health Partners. LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Stamford, Connecticut

Conditions: Soft Tissue Injuries
Interventions: Licart™ (diclofenac epolamine) topical system; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 6 Years to 45 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Little Rock, Arkansas • La Palma, California • DeLand, Florida + 8 more

Search by objective public record fields.

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

Evaluation of the Atlas Genetics io® CTNG System

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury